Versartis Sets IPO Range

Moutain View-based Versartis, a biopharmaceuticals firm developing treatment for endocrine disorders, has set its IPO range at between $16.00 and $19.00 per share. The startup said it is looking to list on the NASDAQ Global Market as VSAR. The offering will net the company around $100.5M. Versartis is backed by New Leaf, Index Ventures, Advent Venture Partners, Aisling Capital, Soffinova Ventures, along with others.